These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26465999)

  • 1. Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Lal H; Cunningham AL; Heineman TC
    N Engl J Med; 2015 Oct; 373(16):1576-7. PubMed ID: 26465999
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Fielding JE; Lambert SB
    N Engl J Med; 2015 Oct; 373(16):1576. PubMed ID: 26466001
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    George IA; Lawrence SJ
    N Engl J Med; 2015 Oct; 373(16):1575-6. PubMed ID: 26466000
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
    Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
    N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In adults ≥ 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster at a mean 3.7 years.
    Sacks HS
    Ann Intern Med; 2017 Jan; 166(2):JC5. PubMed ID: 28114461
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes Zoster Vaccination: Controversies and Common Clinical Questions.
    Van Epps P; Schmader KE; Canaday DH
    Gerontology; 2016; 62(2):150-4. PubMed ID: 26184711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.
    Lu PJ; Euler GL; Harpaz R
    Am J Prev Med; 2011 Feb; 40(2):e1-6. PubMed ID: 21238856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new vaccine to prevent herpes zoster.
    Cohen JI
    N Engl J Med; 2015 May; 372(22):2149-50. PubMed ID: 25916342
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary regarding: Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. H Lal, AL Cunningham, O Godeaux et al., N Engl J Med 372:2087-2096, 2015.
    Yancey KB
    Dermatol Ther; 2016 Sep; 29(5):300-301. PubMed ID: 26798973
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes zoster vaccination in people aged 50-59 years.
    Li HT; Lu S; Liu JM
    Clin Infect Dis; 2012 Apr; 54(7):929-30. PubMed ID: 22291102
    [No Abstract]   [Full Text] [Related]  

  • 15. Herpes zoster vaccine: a shot to maintain wellbeing.
    Michel JP
    Aging Clin Exp Res; 2015 Feb; 27(1):1-3. PubMed ID: 25585545
    [No Abstract]   [Full Text] [Related]  

  • 16. Herpes zoster prevention: A difficult problem to solve.
    Esposito S; Principi N
    Vaccine; 2018 Aug; 36(36):5442-5448. PubMed ID: 28784283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of Protection for Herpes Zoster Vaccine: Evaluating Candidate Immunological Variables.
    Dunning AJ
    J Infect Dis; 2015 Nov; 212(9):1521. PubMed ID: 25985903
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why should older adults receive the shingles vaccine?
    Harkness TL
    J Gerontol Nurs; 2010 Oct; 36(10):51-5. PubMed ID: 20506935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.
    Brisson M; Pellissier JM; Levin MJ
    Clin Infect Dis; 2007 Dec; 45(11):1527-9. PubMed ID: 17990240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.